Physician

Mark Floyd, MD

According to 2025 Medicare claims, Mark Floyd, MD (NPI: 1144595539) practices hematology/oncology in the College Station-Bryan, TX market, with the plurality of this provider's patient population coming from Brazos, TX. This provider's primary affiliated billing organization is BRAZOS VALLEY HEMATOLOGY ONCOLOGY ASSOCIATES, PA (NPI: 1376594432; TIN: 742803009) and primary practice location at 77802-2585.

Floyd's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 618 traditional Medicare patients, billed 182,447 HCPCS/CPT codes, and received $3,195,094 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,718 prescription claims across 287 beneficiaries totaling $4,864,462 in drug costs, led by Erleada (Apalutamide). DME data shows 32 claims. Open Payments data shows 72 records totaling $1,824. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $110,177 to $3,195,094. Similarly, Part D prescription costs have moved sharply higher in recent years, from $472 to $4,864,462. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.8M$3.7M2018 Medicare payment: $110,177 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,381,748 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,890,217 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,655,831 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,500,314 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $3,659,022 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,195,094 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20181147,532$110,177
2019275133,395$1,381,748
2020333167,164$1,890,217
2021375237,779$2,655,831
2022425251,389$3,500,314
2023532227,759$3,659,022
2024618182,447$3,195,094

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$2.6M$5.1M2015 Drug cost: $472 (USD; Tot_Drug_Cst)2016 Drug cost: $1,890 (USD; Tot_Drug_Cst)2017 Drug cost: $345 (USD; Tot_Drug_Cst)2018 Drug cost: $51,198 (USD; Tot_Drug_Cst)2019 Drug cost: $786,370 (USD; Tot_Drug_Cst)2020 Drug cost: $2,943,352 (USD; Tot_Drug_Cst)2021 Drug cost: $3,979,737 (USD; Tot_Drug_Cst)2022 Drug cost: $5,126,510 (USD; Tot_Drug_Cst)2023 Drug cost: $4,819,365 (USD; Tot_Drug_Cst)2024 Drug cost: $4,864,462 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151116$472
20161930$1,890
20171123$345
20182983$51,198
2019121617$786,370
20201531,096$2,943,352
20212261,489$3,979,737
20222381,602$5,126,510
20232381,712$4,819,365
20242871,718$4,864,462

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$3.8K$7.5K2019 Medicare payment: $6,187 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $4,693 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $7,538 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $965 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/R31$6,187
2020N/R67$4,693
2021N/R82$7,538
2022N/RN/RN/R
2023N/RN/RN/R
2024N/R32$965

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99215Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more106337$141
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more321649$94
96372Injection of drug or substance under skin or into muscle102288$11
36415Insertion of needle into vein for collection of blood sample4381,336$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count302880$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
ErleadaApalutamide551,650$765,772
CabometyxCabozantinib S-Malate20600$480,296
ScemblixAsciminib Hydrochloride18540$389,688
OjjaaraMomelotinib Dihydrochloride14420$383,789
SprycelDasatinib21630$301,219

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J8521Capecitabine, oral, 500 mgNN/R17$721
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R15$245

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.72$1,824Dendreon Pharmaceuticals LLC
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Mark Floyd, MD?

Tedicare shows public-source Medicare data for Mark Floyd, MD (NPI 1144595539), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Floyd, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Floyd, MD?

Mark Floyd, MD is linked to BRAZOS VALLEY HEMATOLOGY ONCOLOGY ASSOCIATES, PA (billing NPI 1376594432) in the available physician profile data.

Does Mark Floyd, MD have Open Payments data?

Mark Floyd, MD has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.